Literature DB >> 14521328

Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.

Adrian S Ray1, Raymond F Schinazi, Eisuke Murakami, Aravind Basavapathruni, Junxing Shi, Suzana M Zorca, Chung K Chu, Karen S Anderson.   

Abstract

Beta-D and beta-L-enantiomers of 2',3'-dideoxycytidine analogues are potent chain-terminators and antimetabolites for viral and cellular replication. Seemingly small modifications markedly alter their antiviral and toxicity patterns. This review discusses previously published and recently obtained data on the effects of 5- and 2'-fluorine substitution on the pre-steady state incorporation of 2'-deoxycytidine-5'-monophosphate analogues by HIV-1 reverse transcriptase (RT) in light of their biological activity. The addition of fluorine at the 5-position of the pyrimidine ring altered the kinetic parameters for all nucleotides tested. Only the 5-fluorine substitution of the clinically relevant nucleosides (-)-beta-L-2',3'-dideoxy-3'-thia-5-fluorocytidine (L-FTC, Emtriva), and (+)-beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D-D4FC, Reverset), caused a higher overall efficiency of nucleotide incorporation during both DNA- and RNA-directed synthesis. Enhanced incorporation by RT may in part explain the potency of these nucleosides against HIV-1. In other cases, a lack of correlation between RT incorporation in enzymatic assays and antiviral activity in cell culture illustrates the importance of other cellular factors in defining antiviral potency. The substitution of fluorine at the 2' position of the deoxyribose ring negatively affects incorporation by RT indicating the steric gate of RT can detect electrostatic perturbations. Intriguing results pertaining to drug resistance have led to a better understanding of HIV-1 RT resistance mechanisms. These insights serve as a basis for understanding the mechanism of action for nucleoside analogues and, coupled with studies on other key enzymes, may lead to the more effective use of fluorine to enhance the potency and selectivity of antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521328     DOI: 10.1177/095632020301400301

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  9 in total

1.  Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.

Authors:  Jiae Kim; Ligong Wang; Yongfeng Li; Kimberlynne D Becnel; Kathleen M Frey; Scott J Garforth; Vinayaka R Prasad; Raymond F Schinazi; Dennis C Liotta; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2012-04-24       Impact factor: 2.823

2.  Synthesis and antiviral activity of purine 2',3'-dideoxy-2',3'-difluoro-D-arabinofuranosyl nucleosides.

Authors:  Grigorii G Sivets; Elena N Kalinichenko; Igor A Mikhailopulo; Mervi A Detorio; Tami R McBrayer; Tony Whitaker; Raymond F Schinazi
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-05       Impact factor: 1.381

3.  Horizontally acquired genes in early-diverging pathogenic fungi enable the use of host nucleosides and nucleotides.

Authors:  William G Alexander; Jennifer H Wisecaver; Antonis Rokas; Chris Todd Hittinger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-29       Impact factor: 11.205

4.  Synthesis and anti-HIV activity of D- and L-thietanose nucleosides.

Authors:  Hyunah Choo; Xin Chen; Vikas Yadav; Jianing Wang; Raymond F Schinazi; Chung K Chu
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

5.  Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ.

Authors:  Christal D Sohl; Michal R Szymanski; Andrea C Mislak; Christie K Shumate; Sheida Amiralaei; Raymond F Schinazi; Karen S Anderson; Y Whitney Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

6.  In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.

Authors:  Jennifer L Hammond; Urvi M Parikh; Dianna L Koontz; Susan Schlueter-Wirtz; Chung K Chu; Hengameh Z Bazmi; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine.

Authors:  Nicole Bertoletti; Albert H Chan; Raymond F Schinazi; Y Whitney Yin; Karen S Anderson
Journal:  Protein Sci       Date:  2019-08-06       Impact factor: 6.725

8.  Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Authors:  Christal D Sohl; Rajesh Kasiviswanathan; Jiae Kim; Ugo Pradere; Raymond F Schinazi; William C Copeland; Hiroaki Mitsuya; Masanori Baba; Karen S Anderson
Journal:  Mol Pharmacol       Date:  2012-04-18       Impact factor: 4.436

9.  Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.

Authors:  Joy Y Feng; Eisuke Murakami; Suzana M Zorca; Allison A Johnson; Kenneth A Johnson; Raymond F Schinazi; Phillip A Furman; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.